Roivant reports Q4 FY2026 results with $4.3B cash, multiple clinical updates

Roivant reported strong cash position of $4.3 billion and progress across pipeline including IMVT-1402 showing positive rheumatoid arthritis data, brepocitinib Breakthrough Therapy designation, and a $2.25 billion Moderna settlement. The company expects multiple clinical readouts and a commercial launch by end of 2026, supporting its path to profitability.